P613: TLR9 SIGNALLING IS A POTENTIAL TUMOUR ESCAPE MECHANISM FOLLOWING BTKI THERAPY FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA.
E. Kennedy,
S. Mitchell,
T. A. Burley,
T. Liloglou,
R. Johnston,
I. Ashworth,
D. Bak-Blaz,
K. Chamberlain,
E. Ladikou,
S. Mackay,
C. Pepper,
A. G. Pepper
Affiliations
E. Kennedy
1 Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Falmer
S. Mitchell
1 Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Falmer
T. A. Burley
1 Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Falmer
T. Liloglou
2 Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool
R. Johnston
3 Brighton and Sussex University Hospitals NHS Trust, Brighton
I. Ashworth
1 Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Falmer
D. Bak-Blaz
3 Brighton and Sussex University Hospitals NHS Trust, Brighton
K. Chamberlain
3 Brighton and Sussex University Hospitals NHS Trust, Brighton
E. Ladikou
1 Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Falmer
S. Mackay
4 Cell Biology and Drug Discovery and Design Groups, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom
C. Pepper
1 Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Falmer
A. G. Pepper
1 Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Falmer
